Last reviewed · How we verify
NXC-201 CAR-T
NXC-201 CAR-T is a Biologic drug developed by Nexcella Inc.. It is currently in Phase 1 development. Also known as: HBI0101 CAR-T.
At a glance
| Generic name | NXC-201 CAR-T |
|---|---|
| Also known as | HBI0101 CAR-T |
| Sponsor | Nexcella Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis (PHASE1, PHASE2)
- Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis (PHASE2)
- NXC-201 (formerly HBI0101) Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NXC-201 CAR-T CI brief — competitive landscape report
- NXC-201 CAR-T updates RSS · CI watch RSS
- Nexcella Inc. portfolio CI
Frequently asked questions about NXC-201 CAR-T
What is NXC-201 CAR-T?
NXC-201 CAR-T is a Biologic drug developed by Nexcella Inc..
Who makes NXC-201 CAR-T?
NXC-201 CAR-T is developed by Nexcella Inc. (see full Nexcella Inc. pipeline at /company/nexcella-inc).
Is NXC-201 CAR-T also known as anything else?
NXC-201 CAR-T is also known as HBI0101 CAR-T.
What development phase is NXC-201 CAR-T in?
NXC-201 CAR-T is in Phase 1.
Related
- Manufacturer: Nexcella Inc. — full pipeline
- Also known as: HBI0101 CAR-T
- Compare: NXC-201 CAR-T vs similar drugs
- Pricing: NXC-201 CAR-T cost, discount & access